Molecular Partners AG

MOLN

Company Profile

  • Business description

    Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.

  • Contact

    Wagistrasse 14
    Schlieren
    Zurich8952
    CHE

    T: +41 447557700

    https://www.molecularpartners.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    159

Stocks News & Analysis

stocks

BlackRock earnings: Market gains and inflows drive AUM and revenue to record highs

We plan to raise our fair value estimate of BlackRock stock.
stocks

Our view of ANZ’s strategic plan

Trying to please customers and shareholders with a simpler and leaner bank.
stocks

Perplexing buyback from overvalued ASX share

Earnings continue to grow but investor expectations are too high.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,299.0021.900.24%
CAC 407,919.6214.64-0.18%
DAX 4024,236.94150.99-0.62%
Dow JONES (US)46,270.46202.880.44%
FTSE 1009,452.779.900.10%
HKSE25,797.85356.501.40%
NASDAQ22,521.70172.91-0.76%
Nikkei 22547,720.88873.561.86%
NZX 50 Index13,307.4030.410.23%
S&P 5006,644.3110.41-0.16%
S&P/ASX 2008,990.9022.200.25%
SSE Composite Index3,878.5613.340.35%

Market Movers